The striking benefits achieved with emerging treatment options for recalcitrant connective tissue diseases offer the ...
MedPage Today on MSN
Amputation Risk in Diabetes Drops With GLP-1 Drugs, Study Suggests
Association driven by fewer major amputations ...
Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry populationThe company is ...
According to CNIO, among the various kinds of cancer, pancreatic cancer remains one of the deadliest and is a widely known ...
Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is ...
NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational ...
Jerry Shapiro, MD, discusses strategies for treating patients with scarring and nonscarring alopecia.
Annexon (ANNX) stock: high-risk biotech upside from tanruprubart (GBS) & vonaprument (geographic atrophy). Read here for a ...
ABC4 Utah on MSN
Bills impacting transgender medical services advances to house chamber after committee hearing
On Tuesday, the House Health and Human Services Committee heard several legislative bills impacting funding and restrictions for transgender and hormone medical services.
AB Science receives Japanese patent for use of masitinib in progressive forms of multiple sclerosis: Paris Friday, January 23, 2026, 14:00 Hrs [IST] AB Science SA, a pharmaceutica ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results